Drugs / 153 Sm-EDTMP
153 Sm-EDTMP
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00121095 | Jul 2005 → Jun 2008 | prostate neoplasm | Cytogen Corporation | Unknown | No outcome recorded |
| Phase 1/2 | NCT00482378 | Mar 2005 → May 2007 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00429507 | Mar 2007 → Nov 2014 | breast cancer, metastatic carcinoma in the bone | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 153 Sm-EDTMP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00429507 ↗ |
| Known as | Samarium Sm-153 lexidronam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00121095 ↗ |
| Known as | Sm 153 lexidronam | “samarium Sm 153 lexidronam pentasodium IV over 1 minute on day 1” NCT00482378 ↗ |
| Modality | Other / unclassified | “bone-targeting radioisotope agent” NCT00121095 ↗ |
| Route | Intravenous | “You will receive a small amount of 153 Sm-EDTMP, called a tracer dose, through a needle in your vein.” NCT00429507 ↗ |